Developing RNA Therapies for Diseases of the Cardiovascular System and Oncology such as Atherosclerosis and Pulmonary Hypertension


VasoRx is leading the translation of technologies discovered at  Massachusetts Institute of Technology  (M.I.T) and Yale for the delivery of RNAs for the treatment of diseases. With the world’s first approved RNAi therapeutic, the field of RNA medicines is rapidly expanding. VasoRx utilizes novel nanoparticles that  are dramatically expanding the opportunities for developing RNA therapies for diseases of the cardiovascular system as well as oncology.

The Science

Dysfunctional endothelium contributes to more disease than any other tissue in the body. MicroRNAs (miRNAs) and small interfering RNAs (siRNAs) have the potential to help study and treat endothelial cells in vivo by durably silencing multiple genes simultaneously, but efficient RNA delivery has so far remained challenging. Our polymeric nanoparticles discovered at M.I.T made of low molecular weight polyamines and lipids can deliver these RNAs to endothelial cells with high efficiency, thereby facilitating the simultaneous modification of expression of multiple endothelial genes in vivo.

More About the Science

Contact Us

We would love to hear from you.  Please use the form below for general inquiries.

6 + 7 =